Fluorouracil (5-Fluoracil, 5-FU)

目录号：S1209 别名： NSC 19893

Molecular Weight(MW): 130.08

Fluorouracil (5-Fluoracil, 5-FU)是DNA/RNA合成抑制剂，在肿瘤细胞中通过抑制胸苷酸合成酶（TS）而干扰核苷酸合成。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 1091.79	现货
100mg	RMB 1187.43	现货
200mg	RMB 1799.08	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献20篇：

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

Molecules, 2019, 24(12)

PubMed: 31208101 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30889805 ( click the link to review the publication )

Biosci Rep, 2019, 39(4)

PubMed: 30914455 ( click the link to review the publication )

Mol Med Rep, 2019, 19(2):1203-1209

PubMed: 30569135 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(8):1716-1725

PubMed: 29550418 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):151

PubMed: 30005681 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 46(4):1365-1380

PubMed: 29689552 ( click the link to review the publication )

Neuroendocrinology, 2018, 106(1):58-73

PubMed: 28226315 ( click the link to review the publication )

Neuroendocrinology, 2018, 106(4):335-351

PubMed: 28968593 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9385-9391

PubMed: 29946371 ( click the link to review the publication )

Cancer Res, 2017, 77(18):5039-5053

PubMed: 28716899 ( click the link to review the publication )

PLoS One, 2017, 12(5):e0178375

PubMed: 28542590 ( click the link to review the publication )

Cell, 2017, 170(3):548-563

PubMed: 28753429 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(9):1699-706

PubMed: 27212159 ( click the link to review the publication )

Sci Rep, 2016, 6:29382

PubMed: 27387652 ( click the link to review the publication )

J Proteomics, 2014, 113:326-36

PubMed: 25451013 ( click the link to review the publication )

Mol Cell Biochem, 2014, 10.1007/s11010-014-2253-6

PubMed: 25348361 ( click the link to review the publication )

PLoS One, 2013, 8(1):e54595

PubMed: 23355882 ( click the link to review the publication )

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述

Fluorouracil (5-Fluoracil, 5-FU)是DNA/RNA合成抑制剂，在肿瘤细胞中通过抑制胸苷酸合成酶（TS）而干扰核苷酸合成。

靶点

Thymidylate synthase ^[1]
(Tumor cells)

体外研究

Adrucil是一种尿嘧啶类似物，在C-5位置上有一个氟原子。利用和尿嘧啶一致的转运途径快速进入细胞。Adrucil在细胞内转化成几个活性代谢物：氟脱氧尿苷单磷酸盐(FdUMP)，氟脱氧尿苷三磷酸盐(FdUTP) 以及氟尿苷三磷酸盐 (FUTP)。Adrucil的代谢物FdUMP结合到TS核苷酸结合位点，与CH2THF形成稳定的三聚体，进而阻断了正常的底物dUMP的结合，抑制了dTMP的合成。Adrucil代谢物能够插入DNA，导致DNA双链断裂和细胞死亡。Adrucil的促凋亡作用可能和激活肿瘤抑制因子P53有关。P53功能缺失降低细胞对Adrucil的敏感性。^[1]Adrucil抑制存活诱导各种细胞的凋亡。Adrucil 抑制鼻咽癌细胞系CNE2 和 HONE的生存能力^[2]，Adrucil抑制Capan-1细胞的生存能力^[3]，Adrucil抑制HT-29细胞的生存能力^[4]，IC50 分别是 9 μg/mL, 3 μg/mL, 0.22 μM, 2.5 μM。

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
MCF-7	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkK1O\|LDqGkEoB?=	MYrJR\|UxRTJyIN88[{9uVA>?	NXS4OplXOjRyOUWxO\|Y>
HT-29	NY\1XmdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUi3NuKhcMLi	NXzZNmhsUUN3ME6gNlUh\|rypL33M	NEjNOYUzPDB7NUG3Oi=>
HL-60	NEK5N\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVi3NuKhcMLi	NVrSWJZPUUN3ME24MlYxOSEQvHevcWw>	M{XrfVI1ODl3MUe2
NCI-H292	NGPhUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\MV4o4OsLiaNMg	NWDXS5NmUUN3ME6gNlUh\|rypL33M	MnLxNlQxQTVzN{[=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p53 / PUMA / c-PARP; PubMed: 25965911 Oncotarget (A) HCT-116 cells were treated with various doses of 5-FU for 24 hours (B) HCT-116 cells were treated with 200 uM 5-FU, then harvested at different time points after stimulation. The expression of p53, PUMA, cleaved PARP and P-Akt(S473) were detected by western blotting in different conditions.	25965911
Immunofluorescence	caveolin-3; PubMed: 23646193 PLoS One Cells were stained with an antibody against caveolin-3 (green) and with DAPI (blue). (A) control cells (top images), 10 mM 5-FU (middle images), 50 mM 5-FU (bottom images). Merged images are shown at the right of each panel. phospho-histone H3 ; PubMed: 23646193 PLoS One Cells were grown for 24 h, treated with 5-FU and stained with an anti-phospho-histone H3 antibody (red) and with DAPI (blue). (A) control cells, (B) 0.1 mM 5-FU and (C) 1 mM 5-FU. p65 / p-p65(Ser536) / p53 / p-p53(Ser15); PubMed: 24587255 PLoS One E–H, Immunocytochemistry of p65 and p53 induction and localization by 5-FU treatment for the indicated cell lines. p65 (red), phosphor-p65 (Ser536; red), p53 (green), phospho-p53 (Ser15; red), and DAPI (blue) staining of the nucleus without (control) and with 5-FU treatment. Sox2 / Oct4 / Nanog / ABCG2; PubMed: 27009861 Oncotarget (A) Immunofluorescence staining of Sox2, Oct4 and Nanog in HBE cells with or without 5-FU treatment. In untreated HBE cells, few Sox2, Oct4 or Nanog-positive cells were observed. After 5-FU treatment, the number of Sox2, Oct4 or Nanog-positive cells increased remarkably. Nuclei were counterstained with DAPI (blue). (B) Immunofluorescence staining of ABCG2 in HBE cells with or without 5-FU treatment. β-catenin; PubMed: 30111797 Exp Mol Med Immunofluorescence detection of β-catenin in HCT-8 cells. Scale bar, 20 μm. non-phospho β-catenin; PubMed: 28588704 Oncol Lett Effect of enhanced WNT signaling in Ell3 OE cells. Localization of non-phosphorylated β-catenin was analyzed by immunocytochemical staining in (A) control MCF-7 and (B) Ell3 OE treated with various 5-FU concentrations.	23646193 24587255 27009861 30111797 28588704
Growth inhibition assay	Cell viability; PubMed: 25965911 Oncotarget Cells viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after (A) 50, 100, 200, or 400 uM 5-FU treatment in HCT116 cells. Cell proliferation; PubMed: 30250641 Oncotarget (A) Cell proliferation assay with resveratrol in HCT116. Cells were treated with resveratrol at 0 ~ 200 μM for 72 hours and applied to MTS assay. (B) HCT116 cells were treated with 5-FU at 0~200 μM for 72 hours. (C)HCT116 cells were treated with resveratrol at 0 ~ 200 μM combined with 5-FU at 10 μM for 72 hours and applied to MTS assay. (D) DLD1 cell proliferation assay with resveratrol at 0 ~ 200 μM for 72 hours. (E) DLD1 cells were treated with 5-FU at 0~ 200 μM for 72 hours. (F) DLD1 cells were treated with resveratrol combined with 5-FU at 10 μM for 72 hours. Error bars represent standard deviation.	25965911 30250641

体内研究

Adrucil在治疗包括结肠癌，乳腺癌等各种癌症中有广泛应用。 ^[1]100毫克/千克 Adrucil显著抑制患有结肠癌小鼠的结肠Colon 38的生长，肿瘤复制时间(TD)，生长延缓因子(GDF)，和T/C分别是26.5 days，4.4, 和14%。^[5]

细胞实验：^[4]	+ 展开 Cell lines: 人类结肠癌细胞系 HT-29 Concentrations: ~25 μM Incubation Time: 7天 Method: 在96孔板中Adrucil处理细胞7天后测量生长抑制(4000 HT-29 细胞/孔，在含10%透析的牛胎儿血清RPMI 1640 培养基中)；细胞附着过夜后加入增加浓度的Adrucil。在培养结束时，细胞用磷酸盐缓冲盐水(pH 7.4)清洗3次，用10%三氯乙酸在4 ℃下固定 60分钟。用去离子水洗5次，加入0.4% 磺酰罗丹明溶液在室温染色15分钟。未被磺酰罗丹明着色的通过1%冰乙酸漂洗去除。然后，着色的细胞蛋白质干燥，溶解于10 mM Tris-HCl。探测器在540nm波长处测定光密度值。 (Only for Reference)
动物实验：^[5]	+ 展开 Animal Models: 38小鼠结肠癌结肠38 Formulation: PBS Dosages: 100毫克/千克 Administration: 每周一次腹腔注射 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	26 mg/mL (199.87 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： saline (warming)	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Fluorouracil (5-Fluoracil, 5-FU) SDF

分子量	130.08
化学式	C₄H₃FN₂O₂
CAS号	51-21-8
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	NSC 19893

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03196180	Not yet recruiting	High Grade Cervical Intraepithelial Neoplasia\|p16 Positive Neoplastic Cells Present	National Cancer Institute (NCI)	July 31 2019	Phase 1
NCT03196180	Not yet recruiting	High Grade Cervical Intraepithelial Neoplasia\|p16 Positive Neoplastic Cells Present	National Cancer Institute (NCI)	July 31 2019	Phase 1
NCT03883919	Not yet recruiting	Pancreatic Cancer\|Pancreas Cancer\|Cancer of the Pancreas	Washington University School of Medicine\|Ipsen	June 30 2019	Phase 1
NCT03883919	Not yet recruiting	Pancreatic Cancer\|Pancreas Cancer\|Cancer of the Pancreas	Washington University School of Medicine\|Ipsen	June 30 2019	Phase 1
NCT03784326	Not yet recruiting	Clinical Stage II Esophageal Adenocarcinoma AJCC v8\|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8\|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8\|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8\|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8\|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8\|Clinical Stage III Esophageal Adenocarcinoma AJCC v8\|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8\|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8\|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8\|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8\|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8\|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8\|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8\|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8\|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	May 31 2019	Early Phase 1
NCT03775265	Not yet recruiting	Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall\|Bladder Urothelial Carcinoma\|Stage II Bladder Cancer AJCC v8\|Stage III Bladder Cancer AJCC v8\|Stage IIIA Bladder Cancer AJCC v8	National Cancer Institute (NCI)	May 9 2019	Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I was wondering if the product #s1209 (5-fluorouracil) is suitable to inject into mice ?
回答：
S1209 is suitable to inject (I.P.) into mice as indicating in this paper: http://www.ncbi.nlm.nih.gov/pubmed/8995503.

研究领域

产品类型

Fluorouracil (5-Fluoracil, 5-FU)

客户使用Selleck该产品发表文献20篇：

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Fluorouracil (5-Fluoracil, 5-FU) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

常见问题及建议解决方法

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品